Genprex (Genprex) Accounts Receivable : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Genprex Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Genprex's accounts receivables for the quarter that ended in Mar. 2024 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Genprex's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $2.29.

Genprex Accounts Receivable Historical Data

The historical data trend for Genprex's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genprex Accounts Receivable Chart

Genprex Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

0.04

Genprex Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Genprex Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Genprex Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Genprex's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Genprex's accounts receivable are only considered to be worth 75% of book value:

Genprex's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(8.217	+	0.75 * 0	+	0.5 * 0	-	3.808
-	0	-	0)	/	1.92259
=	2.29

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Genprex Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Genprex's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Genprex (Genprex) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genprex Inc (NAS:GNPX) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

2DE:Germany

Address

3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746

Website

https://www.genprex.com

Genprex Inc is a clinical-stage gene therapy company. It is a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs.

Executives

Catherine M Vaczy	officer: EVP & Chief Strategy Officer	C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
John Rodney Varner	director, 10 percent owner, officer: Chief Executive Officer	P.O. BOX 162341, AUSTIN TX 78716
Hermant Kumar	officer: Chief Mfgr & Tech Officer	3300 BEE CAVE ROAD, #650-227, AUSTIN TX 78746
Mark Stanley Berger	officer: Chief Medical Officer	140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024
Brent M Longnecker	director	C/O RESOURCES CONNECTION, 695 TOWN CENTER DR, COSTA MESA CA 92626
Moreno Toscano Jose Antonio	director	1501 UNIVERSITY CLUB DRIVE, AUSTIN TX 78732
Wilson William R Jr.	director	1407 ETHRIDGE AVE, AUSTIN TX 78703
Michael Thomas Redman	officer: EVP & Chief Operating Officer	16402 EMILIA COURT, SPRING TX 77379
John N Bonfiglio	director	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Genprex, Inc.	director, 10 percent owner, officer: Chief Executive Officer	1601 TRINITY STREET, BLDG. B, SUITE 3.322, AUSTIN TX 78712
Julien L Pham	officer: Chief Operating Officer	944 DORCHESTER AVE #56, BOSTON MA 02125
Jack A Roth	10 percent owner	6516 BROMPTON ROAD, HOUSTON TX 770055
Christy M. Nance	10 percent owner	8305 SCENIC RIDGE COVE, AUSTIN TX 78735
Ryan M. Confer	officer: Chief Financial Officer	1000 SAN MARCOS ST. #460, AUSTIN TX 78702
Robert W. Pearson	director	3001 MEANDERING RIVER COURT, AUSTIN TX 78746